Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.

IF 3.1 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2026-09-01 Epub Date: 2026-09-20 DOI:10.1080/14796694.2026.2732570

Anezka Zemankova, Bohuslav Melichar, Michal Eid, Alexandr Poprach, Jindrich Kopecky, Tomas Buchler, Darja Sustrova, Sarka Stuhlova, Jan Dvorak, Zuzana Donatova, Pavel Vlcek, Katerina Zychackova, Jana Katolicka, Tomas Blazek, David Vrana, Ondrej Fiala, Petra Majkova, Adam Cepa, Hana Studentova

{"title":"Translating avelumab maintenance into clinical practice: nationwide outcomes in Czech patients with advanced or metastatic urothelial carcinoma.","authors":"Anezka Zemankova, Bohuslav Melichar, Michal Eid, Alexandr Poprach, Jindrich Kopecky, Tomas Buchler, Darja Sustrova, Sarka Stuhlova, Jan Dvorak, Zuzana Donatova, Pavel Vlcek, Katerina Zychackova, Jana Katolicka, Tomas Blazek, David Vrana, Ondrej Fiala, Petra Majkova, Adam Cepa, Hana Studentova","doi":"10.1080/14796694.2026.2732570","DOIUrl":null,"url":null,"abstract":"Background: Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement registry for avelumab maintenance. The objective was to assess the effectiveness and safety in routine clinical practice.Methods: Registry data were collected between October 2021 and January 2024. Primary endpoint was overall survival (OS) from avelumab 1L maintenance; secondary endpoints included progression-free survival (PFS) and safety.Results: At data cutoff, 107 patients with la/mUC were treated with avelumab 1L maintenance, the median age was 72 years (range, 45-92), and the median follow-up was 8.2 months. Fifty-five patients (51.4%) received 1L cisplatin-based chemotherapy, 46 (43.0%) carboplatin-based chemotherapy, and six (5.6%) switched between regimens. Median OS was not reached, the 12- and 18-month OS rates were 79.3% and 68.0%. Limitations include low number of patients, retrospective design, and short follow-up.Conclusions: These clinical outcomes are consistent with the JAVELIN Bladder 100 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance in patients with la/mUC that has not progressed with 1L PBC.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2709-2715"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2026.2732570","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement registry for avelumab maintenance. The objective was to assess the effectiveness and safety in routine clinical practice.

Methods: Registry data were collected between October 2021 and January 2024. Primary endpoint was overall survival (OS) from avelumab 1L maintenance; secondary endpoints included progression-free survival (PFS) and safety.

Results: At data cutoff, 107 patients with la/mUC were treated with avelumab 1L maintenance, the median age was 72 years (range, 45-92), and the median follow-up was 8.2 months. Fifty-five patients (51.4%) received 1L cisplatin-based chemotherapy, 46 (43.0%) carboplatin-based chemotherapy, and six (5.6%) switched between regimens. Median OS was not reached, the 12- and 18-month OS rates were 79.3% and 68.0%. Limitations include low number of patients, retrospective design, and short follow-up.

Conclusions: These clinical outcomes are consistent with the JAVELIN Bladder 100 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance in patients with la/mUC that has not progressed with 1L PBC.

查看原文本刊更多论文

将avelumab维持转化为临床实践：捷克晚期或转移性尿路上皮癌患者的全国结果

背景：在捷克共和国，对于非进展性疾病患者，铂基化疗（PBC）加avelumab一线（1L）维持治疗是局部晚期或转移性尿路上皮癌（la/mUC）的标准治疗方案。我们报告了对阿韦单抗维持的国家报销登记的回顾性分析结果。目的是评估在常规临床实践中的有效性和安全性。方法：于2021年10月至2024年1月收集登记资料。主要终点是阿韦单抗1L维持期的总生存期（OS）；次要终点包括无进展生存期（PFS）和安全性。结果：截至数据截止，107例la/mUC患者接受了avelumab 1L维持治疗，中位年龄为72岁（范围45-92岁），中位随访时间为8.2个月。55例（51.4%）患者接受了1L顺铂为基础的化疗，46例（43.0%）接受了卡铂为基础的化疗，6例（5.6%）患者在方案之间切换。中位OS未达到，12个月和18个月OS率分别为79.3%和68.0%。局限性包括患者数量少、回顾性设计和随访时间短。结论：这些临床结果与JAVELIN膀胱100试验和其他现实世界的研究一致，支持avelumab作为未进展为1L PBC的la/mUC患者1L维持的有效性和良好的安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.